Surviving sepsis in the era of antibiotic resistance: Are there any alternative approaches to antibiotic therapy?

Microbial Pathogenesis

Volumn 80, Issue , 2015, Pages 7-13

  Uppu, Divakara S S M ^a   Ghosh, Chandradhish ^a   Haldar, Jayanta ^a  

^a JAWAHARLAL NEHRU CENTRE FOR ADVANCED SCIENTIFIC RESEARCH   (India)

Author keywords

Antibiotics; Antimicrobial peptides; Sepsis; TNF

Indexed keywords

ALEXIDINE; ANTIINFECTIVE AGENT; ARYL AMIDE FOLDAMER; BACTERIUM LIPOPOLYSACCHARIDE; CATHELICIDIN ANTIMICROBIAL PEPTIDE LL 37; CATIONIC ANTIMICROBIAL PEPTIDE; CECROPIN B; CHLORHEXIDINE; DAPTOMYCIN; DROTRECOGIN; HEMOGLOBIN; IMIPENEM; INDOLICIDIN; INTERLEUKIN 1BETA; INTERLEUKIN 6; LACTIC ACID; LIPOTEICHOIC ACID; NATURAL ANTIMICROBIAL PEPTIDE; OXACILLIN; PEPTIDE BAC2A; PEPTIDOGLYCAN; PIPERACILLIN; POLYMYXIN B; POLYPEPTIDE ANTIBIOTIC AGENT; SYNTHETIC ANTIMICROBIAL PEPTIDE; SYNTHETIC MIMIC ANTIMICROBIAL PEPTIDE 4; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANCOMYCIN; BIOLOGICAL PRODUCT; IMMUNOLOGIC FACTOR;

ANTI ENDOTOXIN ACTIVITY; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; CLASSIFICATION; CLINICAL FEATURE; CLINICAL PRACTICE; COMBINATION CHEMOTHERAPY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DISEASE SEVERITY; DRUG ACTIVITY; DRUG MECHANISM; DRUG TARGETING; DRUG THERAPY; HEMOGLOBIN BLOOD LEVEL; HUMAN; IMMUNOMODULATION; INNATE IMMUNITY; LACTATE BLOOD LEVEL; MONOTHERAPY; NONHUMAN; OXYGEN THERAPY; PATIENT CARE; RISK BENEFIT ANALYSIS; SEPSIS; SEPTIC SHOCK; STEROID ANTIBIOTIC LOW DOSE HEPARIN VENTILATION WITH LUNG PROTECTIVE STRATEGY ACTIVATED PROTEIN C GLUCOSE HOMEOSTASIS EARLY GOAL DIRECTED THERAPY; STRUCTURE ACTIVITY RELATION; BACTEREMIA; DRUG COMBINATION; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACTEREMIA; BIOLOGICAL PRODUCTS; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HUMANS; IMMUNOLOGIC FACTORS;

EID: 84922629058     PISSN: 08824010     EISSN: 10961208     Source Type: Journal    
DOI: 10.1016/j.micpath.2015.02.001     Document Type: Review

References (46)

1. (last visited on 8th December, 2014). http://www.cddep.org/blog/posts/visualization_series_burden_antibiotic_resistance:indian_neonates.
2. Angus D.C., van der Poll T. Severe sepsis and septic shock. N.Engl. J. Med. 2013, 369(9):840-851.
3. Blankey S., et al. The application of transcriptional blood signatures to enhance our understanding of the host response to infection: the example of tuberculosis. Philos. Trans. R. Soc. B 2014, 369:20130427.
4. Pankla R., et al. Genomic transcriptional profiling identifies a candidate blood biomarker signature for the diagnosis of septicemic melioidosis. Genome Biol. 2009, 10:R127.
5. Khaenam P., et al. Atranscriptomic reporter assay employing neutrophils to measure immunogenic activity of septic patients' plasma. J.Transl. Med. 2014, 12:65.
6. "It's time we ''SALVAGE'' patients with sepsis!!!". http://www.lungindia.com.
7. http://survivesepsis.org/the-sepsis-six/.
8. Bochud P.Y., Glauser M.P., Calandra T. Antibiotics in sepsis. Intensive Care Med. 2001, 27:S33-S48.
9. Horne D., Tomasz A. Release of lipoteichoic acid from Streptococcus sanguis: stimulation of release during penicillin treatment. J.Bacteriol. 1979, 137(3):1180-1184.
10. Cohen J. The immunopathogenesis of sepsis. Nature 2002, 420(6917):885-891.
11. Hotchkiss R.S., Monneret G., Payen D. Sepsis-induced immunosuppression: from cellular dysfunctions to immunotherapy. Nat. Rev. Immunol. 2013, 13(12):862-874.
12. van Langevelde P., et al. Antibiotic-induced release of lipoteichoic acid and peptidoglycan from Staphylococcus aureus: quantitative measurements and biological reactivities. Antimicrob. Agents Chemother. 1998, 42(12):3073-3078.
13. Prins J.M., et al. Release of tumor necrosis factor alpha and interleukin 6 during antibiotic killing of Escherichia coli in whole blood: influence of antibiotic class, antibiotic concentration, and presence of septic serum. Infect. Immun. 1995, 63(6):2236-2242.
14. Pichereau S., et al. Concentration-dependent effects of antimicrobials on Staphylococcus aureus toxin-mediated cytokine production from peripheral blood mononuclear cells. J.Antimicrob. Chemother. 2012, 67(1):123-129.
15. Purswani M., et al. The effect of three broad-spectrum antimicrobials on mononuclear cell responses to encapsulated bacteria: evidence for down-regulation of cytokine mRNA transcription by trovafloxacin. J.Antimicrob. Chemother. 2000, 46(6):921-929.
16. Araujo F.G., Slifer T.L., Remington J.S. Inhibition of secretion of interleukin-1alpha and tumor necrosis factor alpha by the ketolide antibiotic telithromycin. Antimicrob. Agents Chemother. 2002, 46(10):3327-3330.
17. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature 2002, 415(6870):389-395.
18. Hancock R.E.W., Sahl H.G. Antimicrobial and host-defense peptides as new anti-infective therapeutic strategies. Nat. Biotechnol. 2006, 24(12):1551-1557.
19. Bowdish D.M., Davidson D.J., Hancock R.E. Are-evaluation of the role of host defence peptides in mammalian immunity. Curr. Protein Pept. Sci. 2005, 6(1):35-51.
20. Bowdish D.M.E., et al. Impact of LL-37 on anti-infective immunity. J.Leukoc. Biol. 2005, 77(4):451-459.
21. Scott M.G., et al. An anti-infective peptide that selectively modulates the innate immune response. Nat. Biotechnol. 2007, 25(4):465-472.
22. Achtman A.H., et al. Effective adjunctive therapy by an innate defense regulatory peptide in a preclinical model of severe malaria. Sci. Transl. Med. 2012, 4(135).
23. English B.K., et al. Diminished macrophage inflammatory response to Staphylococcus aureus isolates exposed to daptomycin versus vancomycin or oxacillin. Antimicrob. Agents Chemother. 2006, 50(6):2225-2227.
24. Ghiselli R., et al. Cecropin B enhances betalactams activities in experimental rat models of gram-negative septic shock. Ann. Surg. 2004, 239(2):251-256.
25. Zorko M., Jerala R. Alexidine and chlorhexidine bind to lipopolysaccharide and lipoteichoic acid and prevent cell activation by antibiotics. J.Antimicrob. Chemother. 2008, 62(4):730-737.
26. Moore R.A., Bates N.C., Hancock R.E. Interaction of polycationic antibiotics with Pseudomonas aeruginosa lipopolysaccharide and lipid A studied by using dansyl-polymyxin. Antimicrob. Agents Chemother. 1986, 29(3):496-500.
27. Sawyer J.G., Martin N.L., Hancock R.E. Interaction of macrophage cationic proteins with the outer membrane of Pseudomonas aeruginosa. Infect. Immun. 1988, 56(3):693-698.
28. Piers K.L., Hancock R.E. The interaction of a recombinant cecropin/melittin hybrid peptide with the outer membrane of Pseudomonas aeruginosa. Mol. Microbiol. 1994, 12(6):951-958.
29. Larrick J.W., et al. Human CAP18: a novel antimicrobial lipopolysaccharide-binding protein. Infect. Immun. 1995, 63(4):1291-1297.
30. Scott M.G., Yan H., Hancock R.E. Biological properties of structurally related alpha-helical cationic antimicrobial peptides. Infect. Immun. 1999, 67(4):2005-2009.
31. Bowdish D.M.E., et al. Immunomodulatory activities of small host defense peptides. Antimicrob. Agents Chemother. 2005, 49(5):1727-1732.
32. Rosenfeld Y., Sahl H.G., Shai Y. Parameters involved in antimicrobial and endotoxin detoxification activities of antimicrobial peptides. Biochemistry 2008, 47(24):6468-6478.
33. Rosenfeld Y., Lev N., Shai Y. Effect of the hydrophobicity to net positive charge ratio on antibacterial and anti-endotoxin activities of structurally similar antimicrobial peptides. Biochemistry 2010, 49(5):853-861.
34. Thaker H.D., et al. Synthetic mimics of antimicrobial peptides with immunomodulatory responses. J.Am. Chem. Soc. 2012, 134(27):11088-11091.
35. Choi S., et al. De novo design and invivo activity of conformationally restrained antimicrobial arylamide foldamers. Proc. Natl. Acad. Sci. U. S. A. 2009, 106(17):6968-6973.
36. Som A., et al. Identification of synthetic host defense peptide mimics that exert dual antimicrobial and anti-inflammatory activities. Clin. Vaccine Immunol. CVI 2012, 19(11):1784-1791.
37. Findlay B., Mookherjee N., Schweizer F. Ultrashort cationic lipopeptides and lipopeptoids selectively induce cytokine production in macrophages. PLoS ONE 2013, 8(2):e54280.
38. Padhee S., et al. Non-hemolytic alpha-AApeptides as antimicrobial peptidomimetics. Chem. Commun. 2011, 47(34):9729-9731.
39. Li Y., et al. Lipidated cyclic gamma-AApeptides display both antimicrobial and anti-inflammatory activity. ACS Chem. Biol. 2014, 9(1):211-217.
40. Murugan R.N., et al. De novo design and synthesis of ultra-short peptidomimetic antibiotics having dual antimicrobial and anti-inflammatory activities. PLoS One 2013, 8(11):e80025.
41. Carter P.H., et al. Photochemically enhanced binding of small molecules to the tumor necrosis factor receptor-1 inhibits the binding of TNF-α. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(21):11879-11884.
42. He M.M., et al. Small-molecule inhibition of TNF-α. Science 2005, 310:1022-1025.
43. Kohno T., et al. Binding characteristics of tumor necrosis factor receptor-Fc fusion proteins vs anti-tumor necrosis factor mAbs. J.Investig. Dermatol. Symp. Proc. 2007, 12:5-8.
44. Sheridan C. Small molecule challenges dominance of TNF- α inhibitors. Nat. Biotechnol. 2008, 26(2):143-144.
45. Doi K., et al. Animal models of sepsis and sepsis-induced kidney injury. J.Clin. Investig. 2009, 119(10):2868-2878.
46. Seok J., et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(9):3507-3512.